Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.

Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.

Abstract: We disclose a colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5–40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described.

Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.

Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.

Abstract: The present invention provides a dosage form for the treatment of bacterial, viral or fungal conditions which comprises, a pharmaceutically acceptable acidifying agent in an amount sufficient to reduce the pH at an environment of use to below pH4, and a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor; wherein said acidifying agent and said source of nitrite ions or nitrate precursor are separately disposed in respective pharmaceutically acceptable carriers for admixture at the intended environment of use to release NO or NO2 ions. The invention also provides delivery systems for the topical medicament.

Abstract: A genital wart treatment for treating and removing genital warts. The genital wart treatment includes the acts of dissolving a volume of particulate potassium permanganate in a volume of water to form a treatment solution, and repeatedly performing over a duration of time a treatment application comprising the acts of applying the treatment solution on to genital warts and surrounding skin of a subject to wet the genital warts and surrounding skin with the treatment solution, applying a styptic to the wet genital warts and surrounding skin, and then removing an outermost layer of skin on the genital warts.

Abstract: In order to prevent conception and/or the spread of sexually transmitted diseases (STD's) one or more lectins capable of binding sperm and/or the pathogenic microorganisms responsible for STD's are administered to the vagina prior to sexual intercourse. The lectins immobilize the sperm to render them incapable of fertilization and also bind to the microorganisms to render them non-pathogenic or to the cells to prevent infection by the microorganisms. Lectins can also be administered to treat sexually transmitted vaginal infections. The invention also encompasses a device for to be placed in the vault of the vagina which comprises a ring which surrounds the cervix and a membrane spanning the central aperture of the ring to prevent the direct contact of ejaculate with the cervical tissues. The device is impregnated or coated with lectins and releases them into the vaginal environment over a period of time.

Abstract: A lipid emulsion suitable for use as a parenteral or enteral foodstuff, wherein the lipid phase is a mixture of long-chain fatty acids in which 15 to 45% of the total fatty acids are essential fatty acids.

Abstract: An anti-viral, anti-bacterial, and anti-cancer agent comprising as the effective component, an alkali extraction of Aspalathus linearis which is preferably obtained after extraction by hot water. The agent serves to treat and prevent bacterial infections; to treat and prevent cancer; and to treat or prevent viral infection, for example, infection caused by retroviruses, such as human T-cell leukemia and the AIDS virus. The agent has no side effects.

Abstract: Methods for preventing and treating microbial infections in the mammalian female lower genital tract such as vulvitis, vaginitis, cervicitis, and endometritis involve the intra-vaginal and/or intra-uterine infusion of a solution containing a pharmacologically acceptable carrier and chlorine dioxide in an amount ranging from about 5 ppm to 1000 ppm, and having a chlorine dioxide to chlorite ratio of at least 5:1. Typical solutions exhibit a pH compatible with the lower genital tract, e.g., a pH from about 5 to about 7.5. In many embodiments, chlorine dioxide in the solution is produced by reacting a chlorite with a mineral acid and adjusting the pH, by reacting a chlorite with an organic acid having a pK of about 2.8 to 4.2, or by reacting a chlorite at a pH below about 5.5 with a heat-activated saccharide in the presence of an organic acid having a pK of about 2.8 to about 4.2. Sodium chlorite is employed in preferred embodiments.

Abstract: The present invention relates to a method for enhancing white blood cell functioning and metabolism on a mucosal surface of a mammal. The present invention also relates to a method for treating or preventing a condition in a mammal caused by the presence of a disease-causing agent on a mucosal surface or a cutaneous surface wherein the disease-causing agent can be diminished by the actions of the white blood cells. The present invention yet also relates to a method for healing a wound of a mucosal or cutaneous surface. The present invention also relates to compositions for use in such methods.

Abstract: The pharmaceutical, vaginal applicable preparation is characterized in that it contains, homogeneously sub-divided, at least one in water soluble poly-vinyl alcohol, at least one component A, selected from the group consisting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B for the local treatment of sexually transmissible or transmitted, respectively, diseases, and/or for vaginal infections, and occasionally one or more auxiliary agent(s), and in that it is in the form of a film having a thickness of the layer of from 0.05 to 0.5 mm, especially from 0.06 to 0.2 mm, preferably from 0.07 to 0.15 mm.

Abstract: A method of inhibiting sexually transmitted bacteria, such as in gonococcal infections is disclosed, comprising contacting the bacteria with a composition containing D-propranolol, or a pharmaceutically acceptable salt thereof, preferably in a concentration of about 1% to abot 10% and lacking a polyethoxyethanol component.

Abstract: Antibody or antigen containing microparticles for the active or passive immunization of the internal female reproductive organs, comprising: microparticles of an antigen or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said microparticles capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

Abstract: Antibody or antigen containing microparticles for the active or passive immunization of the internal female reproductive organs, comprising: microparticles of an antigen or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said microparticles capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.